Cysteine cathepsin proteases as pharmacological targets in cancer

This publication has 59 references indexed in Scilit:

• Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain
  Proceedings of the National Academy of Sciences, 2007
• Schistosomiasis Mansoni: Novel Chemotherapy Using a Cysteine Protease Inhibitor
  PLoS Medicine, 2007
• An Orally Active Cathepsin K Inhibitor, Furan-2-Carboxylic Acid, 1-{1-[4-Fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), Inhibits Osteoclast Activity in Vitro and Bone Loss in Ovariectomized Rats
  The Journal of Pharmacology and Experimental Therapeutics, 2006
• Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
  Nature Reviews Cancer, 2006
• Overexpression of Stefin A in Human Esophageal Squamous Cell Carcinoma Cells Inhibits Tumor Cell Growth, Angiogenesis, Invasion, and Metastasis
  Clinical Cancer Research, 2005
• Multiple Roles for Cysteine Cathepsins in Cancer
  Cell Cycle, 2004
• Cysteine cathepsins in human cancer
  Biological Chemistry, 2004
• Crystal Structures of Calpain–E64 and –Leupeptin Inhibitor Complexes Reveal Mobile Loops Gating the Active Site
  Journal of Molecular Biology, 2004
• Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells
  Oncogene, 2002
• Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B, in vivo
  FEBS Letters, 1991